



Effective Date ..... 2/15/2024
Next Review Date... 2/15/2025
Coverage Policy Number ..... IP0168

Idecabtagene vicleucel

Table of Contents

Overview ..... 1
Medical Necessity Criteria ..... 1
Authorization Duration ..... 2
Conditions Not Covered..... 2
Coding Information ..... 2
Background..... 3
References ..... 3

Related Coverage Resources

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This policy supports medical necessity review for idecabtagene vicleucel (Abecma®).

Receipt of sample product does not satisfy any criteria requirements for coverage.

Medical Necessity Criteria

Idecabtagene vicleucel (Abecma) is considered medically necessary when the following are met:

Multiple Myeloma, Relapsed or Refractory. Individual meets ALL of the following criteria:

- A. Age 18 years or older
B. Documented diagnosis of multiple myeloma
C. Documentation of relapsed or refractory disease after FOUR or more prior lines of systemic therapy, including ONE from each of the following:
i. An immunomodulatory agent

- Immunomodulatory agents include Thalomid® (thalidomide capsules), Revlimid® (lenalidomide capsules), Pomalyst® (pomalidomide capsules).*
- ii. A proteasome inhibitor  
*Proteasome inhibitors include Velcade® (bortezomib injection), Kyprolis® (carfilzomib injection), Ninlaro® (ixazomib capsules).*
  - iii. An anti-CD38 monoclonal antibody  
*Anti-CD38 monoclonal antibodies include Darzalex® (daratumumab intravenous infusion), Darzalex Faspro™ (daratumumab and hyaluronidase-fihj subcutaneous injection), Sarclisa® (isatuximab-irfc intravenous infusion).*
- D. Has received lymphodepleting chemotherapy (for example, cyclophosphamide and fludarabine) prior to infusion of Abecma
  - E. Documentation of an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  - F. Does not have central nervous system involvement with myeloma
  - G. Does not have presence or history of plasma cell leukemia
  - H. Documentation of no previous treatment with chimeric antigen receptor T-cell (CAR-T) therapy  
*Examples of CAR-T therapy include Breyanzi (lisocabtagene maraleucel intravenous infusion), Carvykti (ciltacabtagene autoleucel intravenous infusion), Kymriah (tisagenlecleucel intravenous infusion), Tecartus (brexucabtagene intravenous infusion), and Yescarta (axicabtagene intravenous infusion).*
  - I. Medication is prescribed by, or in consultation with, a Hematologist or Oncologist

**Dosing.** Up to 460 x 10<sup>6</sup> CAR-positive T-cells administered intravenous as a single dose.

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

## Authorization Duration

Authorization is for one-time approval, a single dose.

## Conditions Not Covered

Any other use is considered experimental, investigational or unproven, including the following (this list may not be all inclusive):

**Repeat administration of Idecabtagene vicleucel (Abecma)**

## Coding Information

- 1) This list of codes may not be all-inclusive.
- 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

CPT® Codes	Description
0537T	Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day
0538T	Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (e.g., cryopreservation, storage)

0539T	Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for administration
0540T	Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous

HCPCS Codes	Description
Q2055	Idecabtagene vicleucel, up to 460 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

## Background

### OVERVIEW

Abecma, a B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy, is indicated for the treatment of adults with relapsed or refractory **multiple myeloma** after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.<sup>1</sup> Abecma is a chimeric antigen receptor T-cell (CAR-T) therapy.

Abecma is supplied in one or more frozen infusion bags contain a suspension of genetically modified autologous chimeric antigen receptor (CAR)-positive T-cells in 5% dimethyl sulfoxide.<sup>1</sup>

### Guidelines

The National Comprehensive Cancer Network (NCCN) clinical practice guidelines for multiple myeloma (version 3.2023 – December 8, 2022) recommend Abecma for the treatment of previously treated multiple myeloma after at least four prior treatment regimens.<sup>2,3</sup> Patients should receive a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody before receiving Abecma.

### Safety

Abecma has a Boxed Warning for cytokine release syndrome, neurologic toxicity, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, and prolonged cytopenias.<sup>1</sup> Abecma is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called Abecma REMS.

## References

1. Abecma intravenous infusion [prescribing information]. Summit, NJ: Bristol-Myers Squibb; March 2021.
2. The NCCN Multiple Myeloma Clinical Practice Guidelines in Oncology (version 3.2023 – December 8, 2022). © 2022 National Comprehensive Cancer Network, Available at: <http://www.nccn.org>. Accessed on March 20, 2023.
3. The NCCN Drugs & Biologics Compendium. © 2023 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on March 20, 2023. Search term: iclecabtagene.

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna.